This expansion is poised to provide the New Jersey based company's European clientele with time-zone-specific and direct communication channels.
Consumers are increasingly drawn to products containing omega-3 fatty acids, underscoring the need for DolCas Biotech's green-lipped mussel extract, MMP-50.
Green-lipped mussels can contribute towards a healthy musculoskeletal system, due to their naturally occurring anti-inflammatory omega-3 fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Previous research has also identified other types of fatty acids from the mussels. They may also possess anti-inflammatory effects by inhibiting enzymes and proteins that produce inflammation and pain.
DolCas Biotech’s MMP-50 product is a cold-processed, DNA-verified, and clinically researched green-lipped mussel is a nutritional supplement taken from a type of mussel native to New Zealand.
Matrix metalloproteinases (MMPs) are natural enzymes vital for tissue remodelling, wound healing, blood vessel growth, and cell growth mechanisms.
However, research has shown that unchecked MMP activity can have consequences such as joint degeneration, cardiovascular issues, uncontrolled cell growth, and pain syndromes.
DolCas produces its product with a competitive advantage, using fresh, unopened mussels procured directly from ocean farms, eliminating any middleman delays and preserving the integrity of the raw material.
The extraction process is controlled for time and temperature, ensuring that the biological activity of the mussel remains intact throughout the journey from sea to supplement.
According to DolCas Biotech, while green-lipped mussels may be found in various extraction forms within the industry, MMP-50 differentiates itself from other oil extracts, lipid fractions, protein concentrates, or carbohydrate isolates that often lose the essence of the fresh mussel by avoiding cooking, heating, or steaming is involved in the process.
Every batch undergoes rigorous DNA testing to confirm the identity of the clinically studied Perna canaliculus variety of green-lipped mussel.
Previous research has underscored the crucial role of preparation for the clinical benefits of green-lipped mussel products, and DolCas Biotech reports that of the 28 MMP enzymes identified, MMP-50 has demonstrated significant inhibition of MMPs 1-14 in vitro, outperforming its competitors.
Additionally, the product is subjected to bioactivity testing through MMP-inhibitory bioassays, ensuring that the quality and consistency of this raw material are maintained.
Shavon Jackson-Michel, director of medical and scientific affairs for DolCas, emphasises: “The proprietary, cold-processed whole-mussel extract boasts a unique, fully-preserved spectrum of synergistically active compounds, including protein, lipids, anti-inflammatory omega-3s, carbohydrates—including joint-supportive glycosaminoglycans—and a host of vitamins, minerals, and other micronutrients.
“This distinguishes MMP-50 from other green-lipped mussel extracts in the market that are either cooked, or solvent-extracted, concentrated lipid fractions, or defatted formulations that upcycle remnant components of the green-lipped mussel after the lipids have been isolated.”